@openFDA and its related website launched February 27.
GoQii seeks to convert tracked calories, steps and distance into a philanthropic device.
Survey questions can be uploaded as needed.
Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.
A six-month pilot program at the University of Chicago improved glycemic control and engaged patients and HCPs through one key device: a mobile phone.
TapTrak seeks to apply behavioral tracking to clinical trials.
Chronic disease patients seek online support and information, and show little love for branded websites.
Summaries max out at 160 characters and most queries are clinical.
The voice-activated app costs 99 cents.
The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.
Smartphone users, while in the exam room, are more apt to be in "switch mentality," a study finds.
Growing client demand encouraged the agency to make its HCP content capabilities official.
The Kimberly-Clark-backed cold and flu predictor mixes Big Data, and big branding, with an individualized focus.
The agency issued final guidance on mobile apps, saying it will focus only on a subset that present the greatest risk to patients if they don't work correctly.
Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.
The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.
A good percentage of consumers are open to visiting a pharmaceutical company website, an online survey shows, despite a persistent undercurrent of distrust for industry.
A survey by Athenahealth/ePocrates indicates that the digital habits of med students are in sync with those of their professional peers
FDA is concerned state biosimilar legislation could make consumers uneasy about the category, J&J hands $75 million milestone payment for ibrutinib, Consumer Reports gets into drug apps
Allergan asks FDA to reconsider Restatis generics requirements, Incyte's Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna's app alliance makes health local and personal.
Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.
Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.
Medtronic buys up Cardiocom, Novo will file liraglutide to battle obesity, HHS navigates cutback and looks into anti-psychotic prescription rates, Amgen's Neulasta to compete against Teva's Lonquex.
David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.
Patient use of the professional app prompted the latest iteration, and the foundation behind it is set to launch a media push.
The duo whose nonprofit served as neutral ground for getting FDA and industry talking about digital marketing is starting a for-profit research and advisory firm.
The months-old app seeks to become an all-in-one HCP tool and work on a 3.0 version is already in place.
Roche buys diagnostics firm, and a study shows women are major mHealth users; plus: librarians enlisted to help navigate healthcare reform.
CMI/Compas says mobile-ad recall is low but growing, and that smartphones rule professional mobile use.
Medscape asked and doctors shared what they hate about most medical apps, Livestrong merch hits the clearance rack, healthcare reform savings begin to surface, Lilly releases early RA drug trial results